scPharmaceuticals (SCPH) TD Cowen 45th Annual Healthcare Conference summary

Key learnings and product performance

• FUROSCIX has shown rapid and consistent patient relief, with strong positive feedback from both patients and physicians.

• Majority of use remains pre-hospitalization, but post-hospitalization and home health use are increasing, especially in IDNs.

• Operational improvements include a new hub for better satisfaction, increased e-prescribing, and more efficient in-service training.

• Class IV patients, though only 10% of the base, are driving higher average script sizes and are expected to represent up to 25% of usage over time.

• Class IV indication has enabled deeper penetration into heart failure clinics, expanding access and outreach.

Market expansion and strategy

• Early intervention with FUROSCIX reduces hospitalizations by 37% and improves dyspnea scores, supporting a shift to earlier use.

• Medicare redesign lowering patient out-of-pocket caps to $2,000 is expected to significantly boost fill rates and prescribing confidence.

• IDNs are becoming a major growth channel due to their ability to recognize medical cost offsets, unlike PBMs.

• National sales force expansion and entry into Puerto Rico are broadening market reach.

• Nephrology is expected to contribute 35-40% of peak sales, with CKD approval lifting both nephrology and heart failure segments.

CKD launch readiness and nephrology insights

• Launch preparations for CKD include training, marketing materials, and engagement with key nephrology networks.

• Nephrologists are more aggressive in fluid management and receptive to FUROSCIX’s 100% bioavailability.

• Educational initiatives include protocol development with major nephrology practices and planned registry studies.

• National launch will leverage existing IDN relationships and direct prescribing channels.